Correction to Biogen Treads Tricky Path Between Politicians, Investors Article
August 18 2017 - 7:19PM
Dow Jones News
Data published by the National Multiple Sclerosis Society show
that Biogen, along with rival companies such as Teva Pharmaceutical
Industries and Novartis Pharmaceuticals, haven't been shy about
raising the list prices of these medicines. "Biogen Treads Tricky
Path Between Politicians, Investors," at 10:43 a.m. EDT, in the
third paragraph incorrectly included Roche Pharmaceuticals among
the companies that have raised the list prices of their multiple
sclerosis medicines.
(END) Dow Jones Newswires
August 18, 2017 19:04 ET (23:04 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
Teva Pharmaceutical Indu... (NYSE:TEVA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Teva Pharmaceutical Indu... (NYSE:TEVA)
Historical Stock Chart
From Sep 2023 to Sep 2024